Last $0.46 USD
Change Today 0.00 / 0.00%
Volume 0.0
FPMI On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

fluoropharma medical inc (FPMI) Snapshot

Open
$0.42
Previous Close
$0.46
Day High
$0.46
Day Low
$0.42
52 Week High
04/9/14 - $0.92
52 Week Low
11/13/14 - $0.35
Market Cap
13.4M
Average Volume 10 Days
33.4K
EPS TTM
--
Shares Outstanding
29.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUOROPHARMA MEDICAL INC (FPMI)

Related News

No related news articles were found.

fluoropharma medical inc (FPMI) Related Businessweek News

No Related Businessweek News Found

fluoropharma medical inc (FPMI) Details

FluoroPharma Medical, Inc., a biopharmaceutical company, is engaged in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. The company’s product portfolio includes BFPET, an imaging agent that has completed Phase Ia clinical trial in stress-testing for patients with presumptive or proven cardiac artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase II clinical trials to assess myocardial metabolism for patients with coronary artery disease. It is also involved in developing VasoPET, a molecular imaging agent for the detection of ‘vulnerable’ coronary artery plaque in patients with CAD. The company has license agreement with Massachusetts General Hospital. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

5 Employees
Last Reported Date: 03/25/14
Founded in 2003

fluoropharma medical inc (FPMI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $343.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $110.0K
Compensation as of Fiscal Year 2013.

fluoropharma medical inc (FPMI) Key Developments

FluoroPharma Medical, Inc. announced delayed 10-Q filing

On 11/14/2014, FluoroPharma Medical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

FluoroPharma Medical, Inc. Announces the Data from its Phase II Clinical Trial of 18-F FCPHA

FluoroPharma Medical, Inc. announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented at the 19th Annual Scientific Session of ASNC, held this weekend, by the lead author of the abstract, Dr. Manuel Cerqueira. In responding to a question regarding a SPECT fatty acid tracer following the presentation, Dr. Cerqueira suggested that while there are no comparative data with these agents, PET with an F-18 label should provide higher image quality than a SPECT agent.

FluoroPharma Medical Deleted From OTCBB

FluoroPharma Medical, Inc.'s common shares has been deleted from OTC Bulletin Board effective July 17, 2014 on account of its ineligibility for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FPMI:US $0.46 USD 0.00

FPMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FPMI.
View Industry Companies
 

Industry Analysis

FPMI

Industry Average

Valuation FPMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUOROPHARMA MEDICAL INC, please visit www.fluoropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.